Skip to main content
Premium Trial:

Request an Annual Quote

Ayasdi Launches Ayasdi Cure, Announces Partnerships with CLC Bio, Others


NEW YORK (GenomeWeb) – Ayasdi has launched Ayasdi Cure, a new application for its platform, Ayasdi Iris, that's designed to support drug development and discovery projects in the pharmaceutical and biotechnology industry.

According to Ayasdi, a Stanford University spinoff, the application enables users to quickly identify compounds, drug targets, biomarkers, and adverse events from a variety of public and private biological and clinical data. Its features include tools for compound and genomic data visualization, and it also lets users access information on molecular pathways from resources such as the Kyoto Encyclopedia of Genes and Genomes.

Ayasdi also announced two technology partnerships this week with Intel and CLC Bio, which is now owned by Qiagen. The partnership with Intel allowed the company to optimize its newest application to run on the Intel Xeon processor thus improving its performance by 400 percent, Ayasdi said. Meanwhile, its agreement with CLC Bio allows the latter to integrate the Ayasdi Cure application with its bioinformatics solutions and to offer the combined product to customers.

Furthermore, the company has signed an agreement with Innovative Medicines Initiative to provide Ayasdi Cure to academic institutions and biopharmaceutical companies that are involved in its Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes initiative, which studies different types of asthma in order to improve disease diagnosis and treatment.